Találati lista | Tudóstér

001-es BibID:	BIBFORM115235
035-os BibID:	(cikkazonosító)1226760 (WoS)001090239400001 (Scopus)85174827391
Első szerző:	Kacsándi Dorottya
Cím:	Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis / Dorottya Kacsándi, Miklós Fagyas, Ágnes Horváth, Edit Végh, Anita Pusztai, Monika Czókolyová, Boglárka Soós, Attila Ádám Szabó, Attila Hamar, Zsófia Pethő, Nóra Bodnár, György Kerekes, Katalin Hodosi, Szilvia Szamosi, Gabriella Szűcs, Zoltán Papp, Zoltán Szekanecz
Dátum:	2023
ISSN:	2296-858X
Megjegyzések:	Introduction The Renin-Angiotensin-Aldosterone system (RAAS) has been implicated in the regulation of the cardiovascular system and linked to rheumatoid arthritis (RA). Little information has become available on the effects of Janus kinase (JAK) inhibition on RAAS. Here we studied the effects of 12-month tofacitinib treatment on angiotensin converting enzyme (ACE), ACE2 production and ACE/ACE2 ratios in RA along with numerous other biomarkers.Patients and methods Thirty RA patients were treated with tofacitinib in this prospective study. Serum ACE concentrations were assessed by ELISA. ACE2 activity was determined by a specific quenched fluorescent substrate. ACE/ACE2 ratios were calculated. We also determined common carotid intima-media thickness (ccIMT), brachial artery flow-mediated vasodilation (FMD) and carotid-femoral pulse-wave velocity (cfPWV) by ultrasound. C-reactive protein (CRP), rheumatoid factor (RF) and anti-citrullinated protein autoantibodies (ACPA) were also determined. All measurements were performed at baseline, as well as after 6 and 12 months of tofacitinib treatment.Results After the dropout of 4 patients, 26 completed the study. Tofacitinib treatment increased ACE levels after 6 and 12 months, while ACE2 activity only transiently increased at 6 months. The ACE/ACE2 ratio increased after 1 year of therapy (p < 0.05). Logistic regression analyses identified correlations between ACE, ACE2 or ACE/ACE2 ratios and RF at various time points. Baseline disease duration also correlated with erythrocyte sedimentation rate (ESR) (p < 0.05). One-year changes of ACE or ACE2 were determined by tofacitinib treatment plus ACPA or RF, respectively (p < 0.05).Conclusion JAK inhibition increases serum ACE and ACE/ACE2 ratio in RA. Baseline inflammation (ESR), disease duration and ACPA, as well as RF levels at various time points can be coupled to the regulation of ACE/ACE2 ratio. The effect of tofacitinib on RAAS provides a plausible explanation for the cardiovascular effects of JAK inhibition in RA.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Frontiers in Medicine. - 10 (2023), p. 1-8. -
További szerzők:	Fagyas Miklós (1984-) (orvos) Horváth Ágnes (1985-) (reumatológus) Végh Edit Karancsiné Pusztai Anita (1989-) (tudományos segédmunkatárs) Czókolyová Mónika (1993-) (molekuláris biológus) Soós Boglárka (1988-) (általános orvos) Szabó Attila Ádám (1996-) (orvos) Hamar Attila Béla (1990-) (általános orvos) Pethő Zsófia (1981-) (reumatológus, immunológus) Bodnár Nóra (1980-) (reumatológus) Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Hódosi Katalin Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Papp Zoltán (1965-) (kardiológus, élettanász) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Pályázati támogatás:	TÁMOP-4.2.4.A/2-11-1-2012*0001 TÁMOP GINOP-2.3.2-15-2016-00050 GINOP ÚNKP-22-5-DE-408 Egyéb ÚNKP-22-3-I-DE-248
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM100404
035-os BibID:	(cikkazonosító)784220
Első szerző:	Kőszegi Zsolt (kardiológus, belgyógyász)
Cím:	Anatomical Assessment vs. Pullback REsting full-cycle rAtio (RFR) Measurement for Evaluation of Focal and Diffuse CoronarY Disease : rationale and Design of the "READY Register" / Kőszegi Zsolt, Berta Balázs, Tóth Gábor G., Tar Balázs, Üveges Áron, Ágoston András, Szücs Attila, Szabó Gábor Tamás, Barta Judit, Szük Tibor, Czuriga Dániel, Komócsi András, Ruzsa Zoltán
Dátum:	2021
ISSN:	2297-055X 2297-055X
Megjegyzések:	Background: The morphology and functional severity of coronary stenosis show poor correlation. However, in clinical practice, the visual assessment of the invasive coronary angiography is still the most common means for evaluating coronary disease. The fractional flow reserve (FFR), the coronary flow reserve (CFR), and the resting full-cycle ratio (RFR) are established indices to determine the hemodynamic significance of a coronary stenosis. Design/Methods: The READY register (NCT04857762) is a prospective, multicentre register of patients who underwent invasive intracoronary FFR and RFR measurement. The main aim of the registry is to compare the visual estimate of coronary lesions and the functional severity of the stenosis assessed by FFR, as well as the RFR pullback. Characterizations of the coronary vessel for predominantly focal, diffuse, or mixed type disease according to visual vs. RFR pullback determination will be compared. The secondary endpoint of the study is a composite of major adverse cardiac events, including death, myocardial infarction, and repeat coronary revascularization at 1 year. These endpoints will be compared in patients with non-ischemic FFR in the subgroup of cases where the local pressure drop indicates a focal lesion according to the definition of ?RFR > 0.05 (for <25 mm segment length) and in the subgroup without significant ?RFR. In case of an FFR value above 0.80, an extended physiological analysis is planned to diagnose or exclude microvascular disease using the CFR/FFR index. This includes novel flow dynamic modeling for CFR calculation (CFRp-3D). Conclusion: The READY register will define the effect of RFR measurement on visual estimation-based clinical decision-making. It can identify a prognostic value of ?RFR during RFR pullback, and it would also explore the frequency of microvascular disease in the patient population with FFR > 0.80. Clinical Trial Registration: ClinicalTrials.gov (NCT04857762).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk resting full-cycle ratio (RFR) microvascular coronary disease fractional flow reserve (FFR) coronary flow reserve (CFR) coronary artery disease
Megjelenés:	Frontiers in Cardiovascular Medicine. - 8 (2021), p. 1-7. -
További szerzők:	Berta Balázs Tóth Gábor G. Tar Balázs (1970-) (orvos) Üveges Áron Ágoston András Szücs Attila Szabó Gábor Tamás (1982-) (kardiológus) Barta Judit (1975-) (kardiológus) Szűk Tibor (1967-) (kardiológus) Czuriga Dániel (1982-) (kardiológus) Komócsi András Ruzsa Zoltán
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM117090
035-os BibID:	(cikkazonosító)1270093 (WoS)001116444000001 (Scopus)85179329820
Első szerző:	Pituk Dóra
Cím:	The association between EPCR gene p.Ser219Gly polymorphism and venous thromboembolism risk : a case-control study, meta-analysis, and a reproducibility study / Pituk Dóra, Miklós Tünde, Schlammadinger Ágota, Rázsó Katalin, Bereczky Zsuzsanna
Dátum:	2023
ISSN:	2297-055X
Megjegyzések:	Background: The rs867186 single-nucleotide polymorphism in the PROCR gene (g.6936A > G, c.4600A > G) results in a serine-to-glycine substitution at codon 219 of endothelial protein C receptor (EPCR). We performed a case-control study followed by an updated meta-analysis of the association between this polymorphism and the risk of venous thromboembolism (VTE).Objective and methods: We enrolled 263 VTE patients and 320 unrelated healthy controls for the case-control study. The total number of cases and controls for the meta-analysis were 5,768 and 30,017, respectively. A new online MetaGenyo Statistical Analysis System software was used to perform the current meta-analysis. Furthermore, a reproducibility study was conducted to validate our results.Results: Among well-defined thrombosis risk factors, Factor V Leiden was more frequent in the VTE group (p < 0.001), while there was no difference in mutation frequency of prothrombin 20210G>A polymorphism between the two groups. There was no difference in the mutation frequency of Factor V Leiden and prothrombin 20210G>A between cases with and without provoking factors and cases with and without VTE recurrence. The rs867186 "G" carriership did not influence the risk of VTE [odds ratio (OR) 1.339; 95% confidence interval (CI): 0.904-1.984] in our study. No significant differences could be demonstrated among the rs867186 genotype frequencies between VTE cases with and without provoking factors (p = 0.430). PROCR rs867186 was associated with an OR of 1.72 (95% CI: 0.95-3.13, p = 0.075) in terms of VTE recurrence. In the meta-analysis, a significant association was found between EPCR Ser219Gly polymorphism and VTE under the dominant model (OR = 1.27, 95% CI: 1.11-1.46, p = 0.0006), the recessive model (OR = 1.60, 95% CI: 1.26-2.04, p = 0.0001), the GG vs. AA contrast model (OR = 1.64, 95% CI: 1.28-2.09, p = 0.0001), and the GA vs. AA contrast model (OR = 1.24, 95% CI: 1.08-1.43, p = 0.002).Conclusion: The rs867186 was not associated with the first VTE risk in our case-control study; however, a tendency to VTE recurrence was observed. Based on the results of our reproducibility study, MetaGenyo is acceptable for meta-analysis in case of genetic epidemiology studies. Although the risk conferred by the rs867186 is mild in all meta-analyses, including ours, identifying patients carrying the minor allele might have an impact on personalized VTE risk assessment, risk-score calculation, and patient management.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Frontiers in Cardiovascular Medicine. - 10 (2023), p. 1-14. -
További szerzők:	Miklós Tünde Schlammadinger Ágota (1971-) (belgyógyász, haematológus) Molnárné Rázsó Katalin (1966-) (belgyógyász, haematológus, klinikai onkológus) Bereczky Zsuzsanna (1974-) (orvosi laboratóriumi diagnosztika szakorvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103252
035-os BibID:	(cikkazonosító)901286 (WoS)000886464200001 (Scopus)85135188784
Első szerző:	Székely Edina Gabriella
Cím:	Low [alfa]2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis / Székely Edina Gabriella, Orbán-Kálmándi Rita, Szegedi István, Katona Éva, Baráth Barbara, Czuriga-Kovács Katalin Réka, Lóczi Linda, Vasas Nikolett, Fekete István, Fekete Klára, Berényi Ervin, Oláh László, Csiba László, Bagoly Zsuzsa
Dátum:	2022
ISSN:	2297-055X
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Frontiers in Cardiovascular Medicine. - 9 (2022), p. 1-14. -
További szerzők:	Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Katona Éva (1961-) (klinikai biokémikus) Baráth Barbara (1991-) (orvosírnok) Czuriga-Kovács Katalin Réka (1981-) (neurológus) Lóczi Linda Molnárné Vasas Nikolett (1987-) (élettanász) Fekete István (1951-) (neurológus, pszichiáter) Fekete Klára (1978-) (neurológus) Berényi Ervin (1964-) (radiológus) Oláh László (1967-) (neurológus) Csiba László (1952-) (neurológus, pszichiáter) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00043 GINOP K120042 OTKA FK128582 OTKA K120633 OTKA UNKP-21-4-1 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: